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Abstract
The introduction of the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines has substantially contributed to the
early detection of different stages of chronic kidney disease (CKD). Several recent studies from different parts of the world
mention a CKD prevalence of between 8 and 13%. There are several reasons the CKD prevalence found in a study of a partic-
ular population is clearly overestimated. The structure of the population pyramid (young or older age) of the study sample
may result in high or low CKD prevalence. The absence of using an isotope dilution mass spectrometry creatinine assay can
be the source of high bias in CKD prevalence. In addition, using an arbitrary single threshold of estimated glomerular filtra-
tion rate (eGFR; <60mL/min/1.73m2) for classifying CKD leads to a substantial ‘overdiagnosis’ (false positives) in the elderly
(>65 years of age), particularly in those without albuminuria (or proteinuria), haematuria or hypertension. It also results in a
significant ‘underdiagnosis’ (false negatives) in younger individuals with an eGFR >60mL/min/1.73m2 and below the third
percentile for their age/gender category. The use of third percentile eGFR rates as a cut-off based on age/gender-specific
reference values of eGFR allows the detection of these false positives and negatives. In the present article, we focus on an
important and frequently omitted criterion in epidemiological studies: chronicity. Indeed, the twomost important factors
introducing a high number (up to 50%) of false positives are lack of confirming proteinuria and the absence of proof of chron-
icity of the eGFR found at first screening. There is an urgent need for quality studies of the prevalence of CKD using represen-
tative randomized samples of the population, applying the KDIGO guidelines correctly.
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CKD. These three letters form one of the most used acronyms in
the nephrology literature. Indeed, CKD (chronic kidney disease)
is the common, general term used to describe the
clinicopathologic state potentially leading to end-stage renal
disease (ESRD), whatever the nature of the underlying patho-
physiological process, from specific genetic or immune diseases
(such lupus nephritis) to more systemic insults (such as diabetic
nephropathy) [1, 2]. In a very real sense, CKD is a generic term.
This acronym, initially promoted by the US-based National
Kidney Foundation Kidney Disease Outcomes Quality Initiative
(KDOQI) [3] and later confirmed and extended by the Kidney
Disease: Improving Global Outcomes (KDIGO) international
guidelines [4], has the advantage that the same language is spo-
ken everywhere. The term CKD has now replaced several other
expressions that were used in the literature, including renal in-
sufficiency, chronic renal failure and chronic renal disease [5, 6].
In these different nomenclatures, one word is common:
‘chronic’. The chronicity of the kidney disease is clearly defined
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Editorial Comment
in the KDIGO guidelines for the evaluation of CKD [4] ‘CKD is
defined as abnormalities of kidney structure or function, pre-
sent for3 months, with implications for health’ [4]. Thus, im-
plicitly, this recommendation assumes that abnormalities are
present at two different times, and so need to be measured at
baseline and then confirmed at a subsequent time, specifically
3 months. As acknowledged by the KDIGO authors, the choice
of the timing (3 months or 90 days) is a bit arbitrary, based more
on clinical experience than clear evidence. This limit of 3
months has the advantage of being clear, explicit and easy to
implement [4]. If the word ‘abnormality’ can encompass differ-
ent concepts, certainly, the two most tested renal abnormalities,
both in clinical practice and research, are the estimated glom-
erular filtration rate (eGFR), by creatinine-based equations, and
the ‘spot’ urine albumin:creatinine ratio (UACR). Sensu stricto,
CKD status can be attributed to a patient only if low eGFR and/or
high UACR have been found at two different times, with at least
a 3-month gap.
Focusing on the eGFR parameter, it is particularly intriguing
that this chronicity criterion is often not considered in clinical re-
search, and still less in renal epidemiology. The majority of pub-
lished epidemiological studies consider the prevalence of CKD in
general or specific populations [1, 7], but the vast majority of
these studies have totally ignored the chronicity part of the CKD
definition. In other words, nearly all studies have considered CKD
for people with an eGFR <60mL/min/1.73 m2 but measured only
once. A study published in the current issue of Clinical Kidney
Journal shares this important limitation [8]. However, this study is
important, even though confined to a particular occupation
(teachers), for several reasons. Good epidemiological data are
scarce in Africa, especially in the sub-Saharan area [9–11].
Moreover, the study focuses on a relatively young and active
population (46.36 8.5-years-old teachers) and they used the
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
creatinine equation without the ethnic ‘African American Black’
coefficient factor, which seems misleading in African non-
American populations [12, 13]. As expected in this young popula-
tion, the prevalence of low eGFR (defined as eGFR <60mL/min/
1.73 m2) with the CKD-EPI creatinine equation was relatively low,
at 1.8%. We question if the prevalence of CKD would have been
still lower if the chronicity criterion had been available. In other
words, can we estimate the impact of confirming low GFR on the
CKD prevalence in epidemiologic studies?
Based on the available literature, the impact of the con-
firmed diagnosis is far from negligible. In the National Health
and Nutrition Examination Survey III, GFR was estimated by the
Modification of Diet in Renal Disease (MDRD) equations. In a
random sample of 98 patients with an eGFR<60 mL/min/
1.73 m2, a second examination (in a median period of only 2
weeks) classified 77% of the same patients in the same category
(stage 3A CKD). Thus 23% who would have been considered as
‘diseased’ had moved to ‘healthy’ after only a second creatinine
measurement [14]. In 2006, Eriksen and Ingebretsen [16] pub-
lished the results of patient and renal survival in the population
of Tromsø, Norway, over a 10-year period. At that time, the
population of Tromsø was 58 000 and 38 241 had one or more
eGFR results available (by the MDRD non-standardized equation
with coefficient 186 [15]) [16]. Among these 38 241 subjects, 6863
(17.9%) had an eGFR <60 mL/min/1.73 m2. The authors applied
the chronicity criterion at 3 months. The CKD prevalence thus
decreased to 3162 (8.3%), as 1526 (3.9%) had no second measure-
ment and, importantly, 2175 (5.7%) had subsequent estimations
>60mL/min/1.73 m2. Therefore, considering only patients with
second measurements available (n¼ 5337), it can be calculated
that 40.7% of subjects with a first eGFR <60mL/min/1.73 m2 will
not be confirmed as being CKD on the second estimation [16]. In
another analysis from the same database (but using the stand-
ardized MDRD equation with coefficient 175 [17]), these authors
also illustrated that the prevalence of CKD is influenced by the
period of time used for the chronicity criterion [18]. If a 3-month
period is considered, the prevalence of CKD was 3.2%, but it
decreased to 2.0% if the chronicity criterion is obtained on a lon-
ger (i.e. 1-year) period [18].
Prospective longitudinal studies studying the slope of GFR in
general or specific populations are scarce [19–22]. In 2015, Inker
et al. [22] proposed such a study with longitudinal creatinine
measurements (and eGFR by the CKD-EPI equation) of 3888 resi-
dents 31–59 years of age in Reykjavik, Iceland, with a mean
follow-up of 256 10 years and baseline eGFR >60mL/min/1.73
m2. In this cohort, the authors calculated the lifetime risk for
CKD stages 3–5. Interestingly, the authors used different CKD
definitions. The first requires two consecutive measurements of
eGFR<60 mL/min/1.73 m2 or one measurement of eGFR<60 mL/
min/1.73 m2 if it was the last measurement of eGFR due to death
or lack of subsequent creatinine measurement or ESRD. The se-
cond requires eGFR<60 mL/min/1.73 m2 on two occasions or
eGFR<60 mL/min/1.73 m2 on the first measurement if the par-
ticipant died before the second measurement or ESRD. The third
requires eGFR<60 mL/min/1.73 m2 on two occasions or one
eGFR<45 mL/min/1.73 m2 if it was at the last measurement of
eGFR due to death or lack of subsequent creatinine measure-
ment or ESRD. The fourth requires only one measurement of
eGFR<60 mL/min/1.73 m2, irrespective of the results of follow-
up measurements and was used for comparison with previous
reports. Among these definitions, the first three integrate the
notion of repeated measurement, whereas the last one is similar
to definitions found in the majority of epidemiological studies.
The results showed major discrepancies in lifetime CKD risk ac-
cording to the definition used, and the differences are especially
relevant with the fourth definition. For example, a woman who
is currently 45 years of age has a lifetime risk of CKD stages 3–5
of 8.6, 7.8, 7.2 and 16.8% with definitions 1, 2, 3 and 4, respect-
ively. In all analyses (men/women, different age categories and
different follow-up), the CKD lifetime risk was systematically
the highest with the definition including a single eGFR result.
Other definitions can lead to variable results in terms of risk.
We must keep in mind that the period of time between two con-
secutive measurements was also variable, but basically much
longer (3–7 years) than the 3-month period required in the
KDIGO definition [22]. The conclusions of this article must thus
be interpreted with caution regarding the purpose of the current
editorial, but these results perfectly illustrate that using a single
eGFR result will lead to a significantly higher prevalence of CKD
[22, 23].
The last study we want to discuss overcomes the shortcom-
ings of the Inker et al. [22] study. In a seminal study, Benghanem
Gharbi et al. [11] studied the prevalence of CKD in a randomized
(voter list) cohort of 10 524 adult subjects in Morocco, represen-
tative of the general population. The authors strictly applied the
CKD definition from the KDIGO guidelines, meaning that every
low GFR (with the MDRD creatinine equation) should be con-
firmed after 3 months by a second measurement; chronicity
was evaluated after 6 and 12 months. In this relatively young
population, the prevalence of a decreased GFR (defined as
eGFR<60mL/min/1.73 m2) was only 1.6%. Among these ‘CKD’
subjects, chronicity was tested in 78.9% (n¼285). When rein-
vestigated after 3 months (or later), 32% of stage 3A CKD and
7.8% of stage 3B subjects had an eGFR>60mL/min/1.73 m2.
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Based on both studies from Benghanem Gharbi et al. [11] and
Eriksen and Ingebretsen [16], it can be suggested that 30–40% of
patients labelled as CKD stage 3A when the diagnosis is based
on only a single eGFR determination could actually move to
‘normal’ eGFR if the measurement is repeated after 3 months.
These subjects could be considered as ‘false-positive’ CKD pa-
tients, questioning the validity of the majority of CKD epidemio-
logical studies.
How can this high rate of false-positive diagnoses be ex-
plained? In the KDIGO perspective, the rationale of the
3-months threshold is to differentiate acute kidney disease
(AKD) from CKD. In this view, the importance of fulfilling the
chronicity criterion is unquestionable, as the care for CKD and
AKD are very different. However, it seems unlikely that AKD ex-
plained very much of the 30% false-positive results, even if this
assertion is based on lack of data. In part, these false-positive re-
sults can be explained by creatinine variability. As with any bio-
logical variable, creatinine can vary physiologically. In other
words, if serum creatinine is repeatedly measured in the same
individual under the same conditions with the same analytical
methods, a variation [coefficient of variation (CV)] will be
observed, i.e. the so-called intra-individual CV (CVI) [24]. This is
also the case for measured GFR which can vary in the same indi-
vidual by 5–10% [25]. At this point, another source of variability
must be added, i.e. the CV due to the analytical imprecision of
the measurement, or analytical CV (CVA). CVA is dependent on
the method (enzymatic or Jaffe) and specific assays used to
measure serum creatinine. Both CVI and CVA determine the
concept of critical difference or least significant change (LSC),
which is defined as the smallest change over a limited period of
time (classically some weeks) between results from the same in-
dividual that is not due to chance. We will consider the Jaffe
methods for creatinine measurement, as these methods are
most frequently used in the epidemiological studies [7].
Globally, for these methods, the LSC can be evaluated at 20%
[26, 27]. For a given man and woman age 60 years with a serum
creatinine value of 1.2 and 0.9mg/dL, respectively, the LSC con-
cept implies that these values could normally vary from 0.96 to
1.44 and 0.72 to 1.08mg/dL, respectively. Using the CKD-EPI
equations and the same examples (1.2 and 0.9mg/dL), the cor-
responding eGFR values will be 65 and 70mL/min/1.73 m2.
However, because of normal variability of serum creatinine, the
repeated eGFR results could be between 52 and 86 and 56 and
91mL/min/1.73 m2, respectively. In some cases, such physio-
logic variations of creatinine will lead to abnormal eGFR values
(<60mL/min/1.73 m2) [27]. The only way to prevent this variabil-
ity is by repeating measurements, even over a short period of
time. To be considered in the global context of clinical research,
additional variability in repeated creatinine measurements can
still occur if the samples are drawn at different moments of the
day and/or in non-fasting conditions, as circadian variation and
the influence of cooked meat intake on serum creatinine are
both well known [1].
The confirmation of CKD by repeating measurements, not-
ably of eGFR, is mandatory. However, some pitfalls must be dis-
cussed. First, as already discussed, the period of time
considered for the application of the chronicity criterion (3
months) will influence the results: the longer the period be-
tween two measurements, the lower the CKD prevalence [18]. If
a too long period of time is used for confirmation, there is a risk
of increasing lost data for follow-up, the risk of increasing non-
available data and also the risk of competing events, such as
death in elderly populations. Second, according to the principle
of regression toward the mean, if creatinine variability can
explain that some positive results (eGFR<60mL/min/1.73m2)
become negative (eGFR>60mL/min/1.73 m2) after a second test,
there is the same risk that the first negative results are actually
false negative and that repeated measurements would have
been positive. However, because the first measurement is nega-
tive, this second measurement is not done. Therefore, to the
best of our knowledge, the potential impact of these potentially
false-negative results on the prevalence of CKD have not been
studied. Third, in some retrospective analyses, with no system-
atic second measurement, there is a high risk of bias by indica-
tion. Indeed, in general, repeated creatinine measurements will
be prone to be done in patients with CKD or at higher risk of
CKD. This point is illustrated in a recent study from Sweden
where the chronicity criterion could have been applied only in
sicker subjects, leading to higher CKD prevalence in patients
with repeated measurements. In this study, the authors also
considered the time average value of different serum creatinine
values, which is highly questionable and not justified by the au-
thors [28].
Until now, we focused on eGFR abnormality, but the same
reasoning can be applied to the UACR. Indeed, confirmation of
albuminuria (or proteinuria) found at the first screening is an-
other essential condition of the KDIGO guidelines before clas-
sifying an individual as having CKD or not. Many factors can
influence albumin excretion, including obesity, age, sex, distant
inflammation, high blood pressure, infection and drug use [29],
resulting in wide fluctuations and hence false positivity of albu-
minuria. Several authors found a high percentage (>50%) of
false-positive albuminuria at low values [urinary UACR 30–50
mg/g; dipstick proteinuria þ], but less at higher values or dip-
stick þþand þþþ [11, 30, 31]. In the same way, CVI or repeat-
ability of UACR is very high (>50%), and this variability is higher
in low UACR ranges (>100%) [32]. Together with the absence of
proof of low eGFR chronicity, this non-confirmation of albumin-
uria (or proteinuria) in almost all epidemiological studies [7, 19]
in the last 15 years results in false positivity of CKD prevalence
of 50% [11]. In addition, since creatinine excretion is in the de-
nominator of the UACR equation, variations in creatinine excre-
tion can influence the results independent of true albumin
excretion rates. Low creatinine excretion (as in sarcopaenic eld-
erly adults, chronic steroid myopathy or strict vegetarians) can
spuriously elevate the UACR value and marked overexcretion of
creatinine (muscle builders or obesity) can falsely lower the
UACR values, leading to CKD misclassification in both circum-
stances [33, 34].
Large grey areas still exist in our knowledge of the true
prevalence of CKD (according to its various causes) at the popu-
lation level. Recent publications have questioned the purported
‘epidemic’ aspect of CKD [1]. But this topic is beyond the scope
of this editorial; however, several other methodological aspects
of CKD epidemiologic studies should be discussed and could ex-
plain, at least in part, the frequent overestimation of the preva-
lence of CKD in the current literature, namely, the choice of
eGFR instead of measured GFR [25], the choice of the equations
for eGFR [35], the choice of the biomarker [36, 37] and the choice
of a unique threshold for CKD (at 60mL/min/1.73 m2) instead
of an age-calibrated threshold [36, 38]. Regarding this last point,
we have advocated an age-sensitive threshold for CKD def-
inition [36, 38], or better still, the use of third percentile eGFR
creatinine levels based on age-/sex-specific reference values [11,
39]. This approach overcomes the false positives; that is, indi-
viduals with a still normal eGFR for their age (>3rd percentile),
especially in case of an absence of renal damage (albuminuria,
proteinuria or hematuria), who might correctly be considered as
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not having CKD at all [11, 36, 38, 40, 41]. Of comparable import-
ance is considering the young group of individuals with findings
leading to a classification of no CKD, that is, no albuminuria
(proteinuria) and a low eGFR for their age (<3rd percentile for
age and sex category), but above the non-age-sensitive thresh-
old of<60mL/min/1.73 m2 used in the KDIGO guidelines. Young
and middle-aged adults with an eGFR of 60–74 mL/min/1.73 m2
but without albuminuria/proteinuria or other signs of kidney
damage may be better classified as ‘false negative’ CKD in our
view [11, 42].
Among all these methodological parameters that have been
briefly discussed, the application of the chronicity criterion is
firmly and unequivocally mandatory in the diagnosis of CKD,
as it is one of the important causes of false positive CKD diag-
nosis in case of non application. In epidemiology, like in life
. . . before acting, think twice!
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